Search

Displaying results 3431 - 3440 of 9886 in total
  1. Drug

    Dendritic cells vaccine

    go.drugbank.com/drugs/DB15803
    Investigational

    The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity

    Synonyms: Recombinant chimeric COVID-19 DC vaccine, Recombinant chimeric COVID-19 epitope DC vaccine;
  2. Drug

    Afabicin

    go.drugbank.com/drugs/DB15268
    Investigational

    Afabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

  3. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  4. Drug

    Nadecnemab

    go.drugbank.com/drugs/DB16677
    Investigational

    Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).

  5. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  6. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.

  7. Drug

    Calfactant

    go.drugbank.com/drugs/DB06415
    ApprovedInvestigational

    Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. … Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical

  8. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms. … Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773].

    Mixtures: L-Methyl-B6-B12, L-Methyl MCSynonyms: L-5-MTHF, L-methylfolate
  9. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777] … QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.

  10. Drug

    Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone

    go.drugbank.com/drugs/DB15235
    Investigational

    Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced

    Synonyms: Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone